Acting Attorney General Todd Blanche told senators Wednesday that the Department of Justice would commit its resources to stopping mail-order mifepristone, pledging to prioritize action against the Biden-era policy that allowed the abortion drug to be shipped directly to women's homes without an in-person doctor visit.
Blanche's commitment, made during a Senate confirmation hearing, marks the clearest signal yet that the Trump administration intends to challenge the regulatory framework that turned medication abortion into an over-the-counter-style transaction conducted through telehealth screens and postal carriers.
The pledge lands at a moment when pro-life organizations, Republican state attorneys general, and conservative senators have grown increasingly frustrated with the pace of federal action on mifepristone, the first drug in a two-pill regimen that has become the most common method of pregnancy termination in the United States.
Under questioning from Republican senators, Blanche left no ambiguity about where the administration stands. As The Hill reported, the acting attorney general told lawmakers he had personally seen evidence of unregulated pills reaching young women from overseas sources.
"You know, I've seen video myself of what appears to be pills coming even from overseas to young women, and doesn't matter who applies for it, anybody can get it. There's no instructions; they just come dumped out of a little plastic bag, and and it's wrong. And I very much commit our resources to stopping this."
That language went further than anything the DOJ had offered publicly on the issue. Blanche also made clear the administration would not defend the regulatory changes the Biden White House pushed through in 2023, when the FDA permanently ended the in-person dispensing requirement for mifepristone.
"We are not in any way defending what Biden and what his administration did."
The acting AG framed the current moment as a turning point. He told senators that the FDA and the Department of Health and Human Services were conducting a genuine safety review of mifepristone for the first time in a decade, a claim that, while not independently verified in the hearing, signals the administration's intent to revisit the drug's regulatory status from the ground up.
"For the first time in a decade, HHS and the FDA are actually taking a real look at what's happening with some of these abortion pills and whether they're actually safe or not."
Blanche's statements did not emerge in a vacuum. They followed a sustained pressure campaign from anti-abortion organizations that had grown openly critical of the administration's pace on the issue, and specifically of the DOJ's legal posture under former Attorney General Pam Bondi.
Under Bondi, the DOJ had sided with the FDA against states challenging the agency's deregulation of mifepristone, arguing that states lacked legal standing to contest federal drug policy. That position infuriated pro-life allies who had expected the Trump administration to back their cause in court.
Nearly 80 anti-abortion groups sent a letter to Blanche urging the DOJ to reverse course and support states fighting the FDA's mail-order abortion framework. Newsmax reported that the coalition included Susan B. Anthony Pro-Life America, whose president, Marjorie Dannenfelser, put the stakes in blunt terms.
"It's inexcusable that the DOJ is actively litigating against pro-life states."
The coalition's letter was equally direct, stating that "pro-life states cannot meaningfully enforce their laws when FDA is siding with mail-order abortionists." The frustration reflected a broader complaint: that the Dobbs decision, which returned abortion policy to the states, had been effectively undermined by a federal drug-approval regime that let pills bypass state restrictions entirely.
Blanche's confirmation hearing gave him a public stage to address that frustration. He did not commit to a specific litigation strategy, declining to go into details when pressed by Republican senators who urged him to settle Louisiana's lawsuit against the FDA. But his rhetoric left little doubt about the direction he intends to take.
The DOJ under Blanche has already shown a willingness to use its authority aggressively on other fronts. The acting AG recently called fraud charges against the Southern Poverty Law Center "egregious" and rejected claims of political motivation, signaling a DOJ comfortable with confrontation.
The central case is Louisiana's lawsuit against the FDA over the agency's 2023 decision to allow mifepristone prescriptions via telehealth and delivery by mail. The U.S. Court of Appeals for the 5th Circuit is set to hear arguments in the case in September.
That timeline creates a narrow window for the administration to decide how it wants to position itself. The DOJ has already filed legal motions asking courts to dismiss or pause state lawsuits, citing the FDA's ongoing safety review. A Trump-appointed federal judge recently paused Louisiana's case pending the review, as the Washington Examiner reported.
But that pause has not satisfied pro-life advocates. Dannenfelser's organization, which plans to spend $160 million on pro-life candidates, demanded that Blanche "immediately" settle the Louisiana case through a consent decree, according to Just The News. The DOJ, however, has opposed Louisiana's motion for expedited oral argument, seeking a hearing by August 31, a posture that has created tension between the administration and its most committed allies on the issue.
An unnamed administration official told reporters that the FDA safety review would likely take six months to complete, though initial results could come sooner. The scope and methodology of that review remain unclear.
The broader Trump DOJ has not been shy about reshaping federal agencies. The administration recently gutted dozens of ATF firearms rules in what amounted to the broadest agency overhaul on record, and the department has pursued high-profile prosecutions that signal its priorities, from a massive FBI-led sweep in Chicago to the prosecution of a former Milwaukee judge for obstructing an ICE arrest.
The core problem for conservative states is structural. Since the Supreme Court overturned Roe v. Wade, numerous states have banned or severely limited access to abortion clinics. But the Biden administration's 2023 rule change created a parallel pipeline: women in those states can obtain mifepristone through mail-order pharmacies, often shielded by "blue state" laws that protect prescribing clinicians from prosecution across state lines.
The result is a system in which state abortion restrictions exist on paper but are routinely circumvented through the mail. Blanche acknowledged this dynamic at the hearing, telling senators that the Biden rules were "wrong" and that the administration wanted to reach "a good result, consistent with President Trump's administrative directive and priorities."
The real-world consequences of unregulated mail-order abortion pills extend beyond policy debates. Louisiana alone has produced three known criminal cases involving mifepristone coercion, including the recent arrest of Jamelle Kelly on felony feticide charges after his daughter unknowingly took the pill at 23 weeks of pregnancy.
Cases like Kelly's illustrate what happens when a powerful drug circulates without the safeguards that normally accompany prescription medication, no in-person consultation, no verification of who is actually requesting the pills, and in some cases, no instructions at all.
For all the forcefulness of his rhetoric, Blanche left significant questions unanswered. He declined to specify what litigation strategy the DOJ would pursue. He did not commit to settling the Louisiana lawsuit, despite pressure from Republican senators to do so. And he offered no timeline for when the administration's policy review would translate into concrete regulatory or legal action.
The Trump administration has left the Biden-era mifepristone regulations in place throughout its tenure so far. That fact sits uneasily alongside the acting AG's confirmation hearing promises. Whether Blanche's words mark the beginning of a genuine policy shift or another round of reassurance without follow-through will depend on what the DOJ actually does in the months ahead, particularly before the 5th Circuit takes up the Louisiana case.
The DOJ has already faced judicial resistance from Biden-appointed judges on other fronts, and any move to restrict mifepristone access will almost certainly draw legal challenges of its own.
Republican senators and pro-life organizations have heard promises before. What they need now is action, the kind that matches the urgency Blanche expressed at the hearing with the legal and regulatory muscle to back it up.
Pledges at confirmation hearings are easy. Following through when the lawsuits land and the political pressure cuts from every direction, that's the part that matters.
